Unfortunately, in early phase trials, heavily pretreated GIST patients only showed moderate responses to therapeutic antibodies against programmed cell death protein 1 (PD1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) [34, 35], and the mechanisms of these treatments are obscure. This evidence concerns the gene PDCD1 and gastrointestinal stromal tumor.